AI Articles and Analysis about Customer analytics

Mobile technology, including smartphones and wearable devices, collects health-related data such as physical activity metrics (e.g., step counts, heart rate), sleep patterns, and self-reported health information through surveys and applications. 

This interview analysis is sponsored by Justt and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This interview analysis is sponsored by Medable and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.Although there is seemingly a constant stream of impressive headlines touting new drug treatments or potential cancer cures, medical breakthroughs occur at a slow pace. It can take upwards of 10 years from the time a medical breakthrough is discovered until it is eventually available in the market.Clinical trials are necessary to test the safety and effectiveness of new treatments. When clinical trials fail before they even start, medical breakthroughs are obviously delayed. Fortunately, the emergence of AI has the potential to change that situation. 

This interview analysis is sponsored by OneTrust and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Kaiser Permanente (KP) is a leading managed care consortium based in Oakland, California. As of September 2024, KP has reported operating revenues of $85.4 billion and operating income of $1.2 billion. KP is pioneering and supporting AI advancements in healthcare by deploying cutting-edge technology to transform how medical organizations communicate, manage risks, and understand patient experiences.

This interview analysis is sponsored by Interactions and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This article is sponsored by Interactions and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Gilead Sciences, a biopharmaceutical company founded in 1987, has emerged as a leader in the development of innovative therapies for a range of diseases, including HIV, liver diseases, and oncology. With a commitment to advancing the field of medicine, Gilead has increasingly recognized the vital role that AI plays in its operations. Gilead Sciences achieved an annual revenue of approximately $28.3 billion in 2024, driven by its robust portfolio, and employs around 18,000 people globally, reflecting its substantial size and reach within the biotech industry​.